Publications by authors named "Samuel Moser"

Claim this Profile
D
Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function.
Oliver Popp, Samuel Moser, Jörg Zielonka, Petra Rüger, Silke Hansen

MAbs· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
Juergen M Schanzer, Katharina Wartha, Ekkehard Moessner, Ralf J Hosse, Samuel Moser

MAbs· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Anja Seckinger, Jose Antonio Delgado, Samuel Moser, Laura Moreno, Brigitte Neuber

Cancer Cell· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Christian Klein, Inja Waldhauer, Valeria G Nicolini, Anne Freimoser-Grundschober, Tapan Nayak, Samuel Moser

Oncoimmunology· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Juergen M Schanzer, Katharina Wartha, Rebecca Croasdale, Samuel Moser, Klaus-Peter Künkele

J Biol Chem· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Ekkehard Mössner, Peter Brünker, Samuel Moser, Ursula Püntener, Carla Schmidt

Blood· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
Claudia Ferrara, Peter Brünker, Tobias Suter, Samuel Moser, Ursula Püntener

Biotechnol Bioeng· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis